Artelo biosciences to present at the 13th congress of the european pain federation on september 20th

Solana beach, calif., sept. 13, 2023 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that professor saoirse o'sullivan, artelo's vice president of translational sciences, will be presenting at the 13th congress of the european pain federation (efic) being held september 20-22, 2023 at the hungexpo exhibition centre in budapest, hungary.
ARTL Ratings Summary
ARTL Quant Ranking